FDG PET for Soft Tissue Sarcoma (Replaced with Section 220.6.17) - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for soft tissue sarcoma, effective May 15, 2026, retiring the standalone policy and folding it into Section 220.6.17 of the National Coverage Determinations manual. Here's what billing teams need to do.

This isn't a minor administrative shuffle. When CMS retires a standalone policy and absorbs it into a broader NCD section, the coverage criteria, documentation requirements, and medical necessity language can shift—sometimes subtly, sometimes significantly. The policy does not list specific CPT or HCPCS codes in the available data, but FDG PET billing for soft tissue sarcoma has historically involved PET scan codes that your team bills under the broader CMS PET imaging coverage framework. Review your charge capture, your prior authorization workflows, and your documentation templates before May 15, 2026.

Quick-Reference Table

CMS FDG PET for Soft Tissue Sarcoma Coverage Criteria and Medical Necessity Requirements 2026

The core issue here is consolidation. CMS is retiring the standalone FDG PET soft tissue sarcoma coverage policy and replacing it with Section 220.6.17 of the NCD manual. That section governs FDG PET scan coverage more broadly across oncologic indications.

What does that mean for your billing team? It means the CMS FDG PET coverage policy your team has been referencing—likely for years—is gone as a standalone document. Any internal cheat sheets, payer policy summaries, or prior authorization templates that cite the old standalone policy need to be updated to reference Section 220.6.17 directly.

The underlying medical necessity framework for FDG PET in soft tissue sarcoma hasn't necessarily changed just because the policy structure changed. But here's the risk: when documentation and prior auth templates reference a retired policy, you're giving payers and Medicare Administrative Contractors a reason to question the claim. That's a claim denial risk you can avoid with a straightforward update.

Under the broader CMS PET imaging coverage framework, FDG PET for oncologic indications has historically required that the scan be used for one of three purposes: diagnosis, staging, or restaging. For soft tissue sarcoma specifically, medical necessity has centered on cases where the PET result will change the patient's management—not just confirm what conventional imaging already shows. If your documentation doesn't clearly tie the FDG PET order to a management-changing clinical decision, CMS coverage is on shaky ground regardless of which policy section applies.

Prior authorization requirements for FDG PET scans vary by Medicare Advantage plan and by Medicare Administrative Contractor jurisdiction. Under traditional Medicare, FDG PET is generally covered without prior authorization when medical necessity is met, but your Medicare Advantage contracts may have different rules. Don't assume the consolidation into Section 220.6.17 changes your prior auth obligations—confirm with each payer before May 15, 2026.

Reimbursement for FDG PET scans is set under the Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment System. This policy retirement does not change the fee schedule rates. What it changes is the documentation framework your claims must support.

CMS FDG PET for Soft Tissue Sarcoma Exclusions and Non-Covered Indications

The available policy data doesn't enumerate specific exclusions in the retired standalone policy. However, based on how CMS has historically treated FDG PET coverage under Section 220.6.17 and related NCD sections, there are well-established non-covered patterns your billing team should understand.

FDG PET scans ordered solely for initial diagnosis—without a tissue biopsy to guide the clinical decision—have consistently faced coverage scrutiny. CMS does not treat PET as a replacement for histologic confirmation of soft tissue sarcoma. If the claim documentation suggests the PET was ordered before or instead of biopsy, expect scrutiny.

Routine surveillance PET scans—meaning scans ordered on a scheduled interval basis without a clinical trigger indicating possible recurrence or progression—are not covered as a general rule. The scan has to serve a specific, documented clinical purpose. "Patient is 12 months post-resection, due for surveillance scan" is not sufficient medical necessity language under CMS guidelines.

Scans for low-grade soft tissue tumors where clinical management won't change based on PET findings have also faced coverage challenges. FDG PET coverage under CMS requires that the imaging result will change patient management. If the treatment plan is fixed regardless of the scan result, the claim is vulnerable.

Coverage Indications at a Glance

The policy data provided does not include specific, enumerated coverage indications from the retired standalone policy. The table below reflects the general CMS FDG PET coverage framework under Section 220.6.17 as it applies to soft tissue sarcoma. If your compliance officer or billing consultant has access to the full text of the new Section 220.6.17, verify these against the actual NCD language before May 15, 2026.

CMS FDG PET Soft Tissue Sarcoma Billing Guidelines and Action Items 2026

The effective date is May 15, 2026. You have a clear deadline. Here's what to do before it arrives.

CPT, HCPCS, and ICD-10 Codes for FDG PET Soft Tissue Sarcoma Under Section 220.6.17

Codes Listed in the Policy Data

The policy data provided for this change does not include specific CPT, HCPCS, or ICD-10 codes. The retired standalone policy and its replacement in Section 220.6.17 are not accompanied by a code list in the available data.

Do not rely on this post alone to determine which codes apply to your claims. Pull the full text of Section 220.6.17 from the CMS NCD manual directly. Cross-reference your existing charge capture codes against that section. If you're unsure which codes your team currently bills for FDG PET in soft tissue sarcoma, that audit is overdue regardless of this policy change.

For reference, FDG PET billing under Medicare has historically involved PET scan procedure codes reported with the appropriate radiopharmaceutical supply code. Your nuclear medicine or radiology billing team will know which codes are active in your charge master. Confirm those codes are consistent with Section 220.6.17 coverage criteria before May 15, 2026.